(6-bromo-imidazolo[1,2-a]pyrazin-8-yl)-(6-morpholin-4-yl-pyridin-3-yl)-amine | 1204428-06-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: (6-bromo-imidazolo[1,2-a]pyrazin-8-yl)-(6-morpholin-4-yl-pyridin-3-yl)-amine
• 英文别名: (6-bromo-imidazo[1,2-a]pyrazine-8-yl)-(6-morpholin-4-yl-pyridin-3-yl)-amine；(6-bromo-imidazo[1,2-a]pyrazin-8-yl)-(6-morpholin-4-yl-pyridin-3-yl)-amine；6-bromo-N-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine
• CAS: 1204428-06-7
• 化学式: C₁₅H₁₅BrN₆O
• 分子量: 375.228
• InChiKey: NWYKVLUZZIRMOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  67.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] IMIDAZOPYRAZINE SYK INHIBITORS<br/>[FR] INHIBITEURS IMIDAZOPYRAZINE DE LA SYK
  申请人：GILEAD CONNECTICUT INC

  公开号：WO2013188856A1

  公开（公告）日：2013-12-19

  Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of an imidazopyrazine compound effective to reduce signs or symptoms of the disease or disorder are provided.

  本发明提供了某些咪唑并吡唑化合物及其药物组合物。还提供了治疗患有某些对Syk活性抑制有响应的疾病和障碍的患者的方法，该方法包括向这样的患者施用足以减少疾病或障碍的症状或体征的咪唑并吡唑化合物。
• Inhibitors of bruton's tyrosine kinase
  申请人：Kondru Rama K.

  公开号：US20100016302A1

  公开（公告）日：2010-01-21

  This application discloses 6-Phenyl-imidazo[1,2-a]pyrazine derivatives according to generic Formulae I-V: wherein, variables Q, R, Y 1 , Y 2 , Y 3 , Y 4 , n, and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-V and at least one carrier, diluent or excipient.

  该应用程序根据通用公式I-V 揭示了6-苯基咪唑并[1,2-a]吡嗪衍生物： 其中，变量Q、R、Y1、Y2、Y3、Y4、n 和m 如本文所述定义，这些衍生物抑制Btk。本文所披露的化合物可用于调节Btk 的活性并治疗与过度Btk 活性相关的疾病。这些化合物进一步可用于治疗与异常B细胞增殖相关的炎症和自身免疫疾病，如类风湿性关节炎。还披露了包含公式I-V 化合物和至少一种载体、稀释剂或赋形剂的组合物。
• NOVEL PHENYLIMIDAZOPYRAZINES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2307418A1

  公开（公告）日：2011-04-13
• US8426409B2
  申请人：——

  公开号：US8426409B2

  公开（公告）日：2013-04-23
• [EN] NOVEL PHENYLIMIDAZOPYRAZINES<br/>[FR] NOUVELLES PHÉNYLIMIDAZOPYRAZINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010006970A1

  公开（公告）日：2010-01-21

  6-Phenyl-imidazo[l,2-a]pyrazine derivatives according to generic Formulae I-V: wherein variables Q, R, Y1, Y2, Y3, Y4, n, and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-V and at least one carrier, diluent or excipient.